Researchers from Taiwan and California, directed by Pr. Alice Yu, have published new data showing that OAcGD2 is a novel marker for breast cancer stem cells, the rare subset of tumor cells that drives tumor progression and disease recurrence .

Researchers have used patient-derived tumors grafted in NOD/SCID mice to demonstrated that the treatment with anti-OAcGD2 antibody, developed by OGD2 Pharma, may have superior anticancer efficacy in breast cancer by targeting cancer stem cells, thereby reducing metastasis and recurrence of cancer.

Cheng JY, Hung JT, Lin J, Lo FY, Huang JR, Chiou SP, Wang YH, Lin RJ, Wu JC, Yu J, Yu AL. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.

Front Immunol. 2022 Jan 3;12:791551. https://pubmed.ncbi.nlm.nih.gov/35046949/